$10.42
0[0.00%]
At close: Apr 23
$10.42
0[0.00%]
After Hours: 4:00PM EDT
Immatics
(NASDAQ:IMTX)Latest News for Immatics Stock (NASDAQ:IMTX)
Immatics Stock (NASDAQ: IMTX)
Categories: All
Thursday, March 21, 2024
- Immatics shares are trading lower after the company reported a year-over-year decrease in Q4 financial results.Benzinga Newsdesk - Mar 21, 2024, 9:28AM
- 12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga Insights - Mar 21, 2024, 9:05AM
- Immatics Q4 GAAP EPS €(1.20) Down From €0.55 YoY, Revenue From Collaboration Agreements €54.00M Down From €172.83M YoY; Cash And Cash Equivalents, And Other Financial Assets Of €425.9M (~$470.6M) Expected To Provide Cash Runway Into 2027Benzinga Newsdesk - Mar 21, 2024, 7:27AM
Monday, March 18, 2024
Thursday, January 18, 2024
Wednesday, January 17, 2024
Wednesday, November 08, 2023
Thursday, November 02, 2023
Tuesday, October 24, 2023
Monday, September 11, 2023
Thursday, August 17, 2023
Thursday, August 10, 2023
Monday, July 24, 2023
- Why Immatics Shares Are Rising TodayNabaparna Bhattacharya - Jul 24, 2023, 10:05AM
- Immatics shares are trading higher after the company announced a $35 million equity investment from Bristol Myers Squibb.Benzinga Newsdesk - Jul 24, 2023, 8:35AM
- Bristol Myers Squibb Has Made A $35 Million Equity Investment In Immatics, With The Purchase Of Around 2.4 Million Shares At $14.461/ShareBenzinga Newsdesk - Jul 24, 2023, 7:09AM
Tuesday, June 27, 2023
Thursday, June 22, 2023
Tuesday, May 16, 2023
- Recap: Immatics Q1 EarningsBenzinga Insights - May 16, 2023, 9:25AM
- Immatics Biotechnologies Granted U.S. Patent #11648276: Immunotherapy against neuronal and brain tumors; #11648292: Immunotherapy against several tumors including gastrointestinal and gastric cancerCharles Gross - May 16, 2023, 7:40AM
- Immatics' Cash Position Of €329.8M, With Cash Runway Into 2025Benzinga Newsdesk - May 16, 2023, 7:19AM
- Immatics Q1 EPS $(0.28) Beats $(0.30) Estimate, Sales $10.51M Miss $13.29M EstimateBenzinga Newsdesk - May 16, 2023, 7:18AM
Tuesday, May 02, 2023
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga Insights - May 2, 2023, 1:31PM
- What's Going On With Immatics Shares TodayVandana Singh - May 2, 2023, 12:25PM
- US Stocks Down; Chegg Crashes After Removing Guidance On ChatGPT ConcernsLisa Levin - May 2, 2023, 10:55AM
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - May 2, 2023, 9:06AM
- Immatics shares are trading higher after the company reported interim clinical data from the ongoing Phase 1b Cohort A monotherapy with ACTengine IMA203 TCR-T targeting PRAME.Benzinga Newsdesk - May 2, 2023, 8:39AM
- Immatics Reports Interim Clinical Data From Ongoing Phase 1b Cohort A Monotherapy With ACTengine IMA203 TCR-T Targeting PRAME; ORR 64%Benzinga Newsdesk - May 2, 2023, 7:10AM
- Immatics Reported Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy With ACTengine IMA203 TCR-T Targeting PRAMECharles Gross - May 2, 2023, 7:10AM
Monday, May 01, 2023
- Bristol-Myers Squibb's Breyanzi Aces Two Lymphoma Studies On Overall Response Rate Endpoint, Plus New CollaborationVandana Singh - May 1, 2023, 11:57AM
- Bristol Myers Squibb Has Exercised Its Option And Entered Into An Exclusive Worldwide License For T Cell Receptor-engineered T Cell Therapy Candidate From Its Ongoing Collaboration With Immatics; Immatics To Receive An Option Payment Of $15MBenzinga Newsdesk - May 1, 2023, 7:05AM
Friday, March 31, 2023
Thursday, March 23, 2023
Tuesday, March 21, 2023
Tuesday, January 24, 2023
Tuesday, January 17, 2023
Tuesday, January 03, 2023
Monday, November 28, 2022
Thursday, November 17, 2022
Tuesday, November 15, 2022
Tuesday, October 25, 2022
- Immatics Biotechnologies Granted U.S. Patent #11479589 Peptides and Combination of Peptides for Use in Immunotherapy Against Lung Cancer, Including NSCLC, SCLC and Other CancersCharles Gross - Oct 25, 2022, 8:17AM
- Immatics Biotechnologies Granted U.S. Patent #11479594 Peptides and Combination of Peptides for Use in Immunotherapy and Methods for Generating Scaffolds for the Use Against Pancreatic Cancer and Other CancersCharles Gross - Oct 25, 2022, 8:14AM
Tuesday, October 11, 2022
Monday, October 10, 2022
- Why Applied DNA Sciences Shares Are Trading Higher By Around 65%, Here Are 54 Stocks Moving In Monday's Mid-Day SessionLisa Levin - Oct 10, 2022, 11:59AM
- Alphatec Holdings, Immatics And Some Other Big Stocks Moving Higher On MondayLisa Levin - Oct 10, 2022, 11:42AM
- Immatics Immunotherapy Candidate Shows Confirmed Responses In Different Solid CancersVandana Singh - Oct 10, 2022, 9:30AM